- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Alagille syndrome (ALGS)
- Meeting Date: March 2026
- Public Summary Document (PSD) March 2026 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2026 PBAC Meeting - (DOCX)
Odevixibat – March 2026
Capsule 200 micrograms, Capsule 400 micrograms, Capsule 600 micrograms, Capsule 1200 micrograms
Last updated
11 March 2026